We categorized the relapse treatment into four groups: ALL-REZ BFM protocols ( 90, 95/96 and ), NOPHO ALL and ALL HR arms. In a prospective and blinded study, the ALL-REZ BFM Study Group .. In the subsequent trial ALL-REZ BFM , this level of MRD after. n = 46; ALL-REZ BFM 95/96, n = 46; ALL-REZ BFM , n = 9). Six/ (3%) cases received palliative treatment for first relapse, and 71/

Author: Kigagrel Arashikasa
Country: Pacific Islands
Language: English (Spanish)
Genre: Software
Published (Last): 27 March 2011
Pages: 353
PDF File Size: 7.18 Mb
ePub File Size: 6.60 Mb
ISBN: 958-2-55234-724-5
Downloads: 66467
Price: Free* [*Free Regsitration Required]
Uploader: Akinokora

Intensive chemo-radiotherapy has been administered before transplantation to reduce the burden of disease and induce immunosuppression in the host. Bone-marrow relapse in paediatric acute lymphoblastic leukaemia.

Early relapse Patients failing to achieve CR2 with the same agents used at primary diagnosis usually do not respond to different drug combinations Intrinsic drug resistance: Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia ALL after first bone marrow or extramedullary relapse.

Donor- vs -recipient NK alloreactivity has emerged as a crucial factor for the outcome of haplo-SCT[ 7273 ]. Adquisition of new genetic alterations at relapse, often involving cell proliferation and B-cell development pathway. In a report by investigators at St. Children Oncology Group; CR: Slow early response was also associated with a higher risk of relapse.

Current approach to relapsed acute lymphoblastic leukemia in children

We hypothesize that thorough analysis of prognostic factors, validation of the current risk stratification and comparison of treatment modalities could be helpful in improving treatment for relapsed childhood ALL. Since patients that relapse after HSCT in CR1 differ substantially from patients treated with chemotherapy only, bf, baseline characteristics, treatment and outcome, they were excluded from all outcome analysis. Comparison of 20002 periods — and — Risk allocation is based on immunophenotype, time and site of relapse see Table 5.


For the BFM group, the end of frontline therapy is as much or even more important than the duration of the first remission. Hfm study reached its predefined early stopping rule for efficacy when 14 complete responses were observed among the first 22 patients enrolled.

ALL-REZ BFM–the consecutive trials for children with relapsed acute lymphoblastic leukemia.

Epratuzumab administration was tolerated with acceptable toxicity, both as a single agent and when combined with chemotherapy. Altogether, of patients Age at primary diagnosis might influence outcome after relapse.

Deletion of IKZF1 and reez in acute lymphoblastic leukemia.

This study was approved by the Ethical Review Board in Stockholm and 20002 conducted in accordance with the Declaration of Helsinski. In contrast, for those with a late first relapse and second relapse, leukemia-free and OS rates were similar after chemotherapy alone and transplantation[ 57 ]. A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia.

Acute lymphoblastic leukaemia; CAN: After remission reinduction, recommendations for continuation therapy include ongoing intensive chemotherapy with or without radiation therapy or SCT. Primary risk groups were not included in the adjusted models since we adjusted for base-line characteristics at diagnosis. These findings are suggestive of a model whereby late relapse is due to the acquisition of diverse secondary events that might occur in a distinct subpopulation such as a leukemic stem cell[ 48 ].

ALL-REZ BFM–the consecutive trials for children with relapsed acute lymphoblastic leukemia.

Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. According to this model, genomic studies carried out in samples alll children at diagnosis and relapse demonstrated the acquisition of new genetic alterations at relapse, often involving cell proliferation and B-cell development xll 45464849 ].


We demonstrate that unfavorable cytogenetics, age ten years or over, T-cell immunophenotype with hyperleukocytosis and Down syndrome were all additional individual prognostic factors in relapsed ALL. More than 6 mo after completion of primary treatment.

Immune cells are genetically modified to express chimeric antigen receptors CAR that contain a target recognition domain linked to an intracellular component that activate a signalling cascade[ 80 ]. Immunophenotype is commonly used in the risk assessment at relapse, but although immunophenotype was a risk factor in the univariate analysis, it was not in the multivariate analysis.

High white blood cell count at diagnosis of childhood acute lymphoblastic leukaemia: Where do we stand in the treatment of relapsed acute lymphoblastic leukemia? Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: Allogeneic SCT is a curative option for several hematologic malignancies and the current availability of rsz different stem cell sources rfz expanded this option for many children.

Please review our privacy policy.

SCT vs continuation of chemotherapy. Recurrent ALL is a relatively common disease for pediatric oncologists, and given the relatively high prevalence of newly diagnosed ALL, relapsed ALL still has a higher incidence than rwz new diagnoses of many of the most common pediatric malignancies and represents one sll the most common childhood cancer.

Monoclonal antibodies directed to cell surface antigens expressed by leukemic blasts epratuzumab, blinatumomab, inotuzumab ozogamicin, and moxetumomab pasudotox, among othersare ideal candidates.